The purpose of this study was to evaluate the efficacy of lymphoscintigraphy and the surgical gamma probe (SGP) with peritumoral injection of99mTc MIBI in sentinel lymph node (SLN) detection in breast cancer regardless of whether metastatic or notMethod: Thirty patients with T1/T2 breast cancer had peritumoral injections of99mTc MIBI (74 MBq/0.2 ml at 4 different locations) at 2, 6 and 24 hours before surgery. Anterior, anterolateral, and lateral spot images were taken at 10, 30, 45, 60 and 120 minutes. Counts were collected from the injection site, affected breast tissue, internal mammaries, axillary and supraclavicular regions, and the contralateral side. Peritumoral blue dye was also injected at surgery. The first lymph nodes with counts twice the background tissue and/or with blue dye uptake were surgically isolated, and histopathological evaluations were made. Modified radical mastectomy was performed on all patients.Results: 23/30 patients had lymph nodes in scintigrams and the sentinel lymph nodes were identified with SGP in 25/30 patients.Conclusion: Lymphoscintigraphy and subsequent SGP detection with peritumoral injection of99mTc MIBI can be used for identifying SLN in breast cancer.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1989 to January 1994.Johns Hopkins Hops Bull 1994–1995; 4: 297–323.
Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment.Breast Cancer Res Treat 1985; 5: 17–21.
Harris JR, Hellman S. Natural history of breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds.Diseases of the Breast. Philadelphia; Lippincott-Raven, 1996.
Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases.Cancer 1987; 59: 682–687.
Danforth DN Jr, Findlay PA, McDonald HD, Lippman ME, Reichert CM, d'Angelo T, et al. Complete axillary lymph node dissection for stage I–II carcinoma of the breast.J Clin Oncol 1986; 4: 655–662.
Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer: an analysis of 259 consecutive patients.Arch Surg 1990; 125: 1144–1147.
Senofsky GM, Moffat FL, Davis K, Masri MM, Clark KF, Robinson DS. Total axillary lymphadenectomy in the management of breast cancer.Arch Surg 1991; 126: 1336–1342.
Kissin MW, Thompson EM, Price AB, Slavin G, Kark AE. The inadequacy of axillary sampling in breast cancer.Lancet 1982; 2: 1210–1212.
Davies GC, Millis RR, Hayward JL. Assessment of axillary lymph node status.Ann Surg 1980; 192: 148–151.
Larson D, Weinstein M, Goldberg I, Silver B, Recht A, Cady B. Edema of the arm as a function of the extent of axillary surgery in patients with Stage I–II carcinoma of the breast treated with primary radiotherapy.Int J Radiat Oncol Biol Phys 1986; 12: 1575–1582.
Ryttov N, Holm NV, Qvist N, Blichert-Toft M. Influence of adjuvant irradiation on the development of late arm lymphedema and impaired shoulder mobility after mastectomy for carcinoma of the breast.Acta Oncol 1988; 27; 667–671.
Ivens D, Hoe AL, Podd TJ, Hamilton OR, Taylor J Royle GT, et al. Assessment of morbidity from complete axillary dissection.Br J Cancer 1992; 66: 136–138.
Dixon M. Sentinel node biopsy in breast cancer.Br Med J 1998; 317: 295–296.
Della Rovere G, Bird PA. Sentinel-lymph-node in breast cancer.Lancet 1998; 352: 421–422.
van Der Wall E. The sentinel node in breast cancer: implications for adjuvant treatment?Eur J Nucl Med 1999; 26 (Suppl): 17–19. (abstract)
Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph node in breast cancer.Lancet 1997; 349; 1668–1669.
Flett MM, Going JJ, Stanton DD, Cooke TG. Sentinel node localization in patients with breast cancer.Br J Surg 1998; 85 (7): 991–993.
Uren RF, Howman-Gilers RB, Thompson JF. Mammary lymphoscintigraphy in breast cancer.J Nucl Med 1995; 36: 1775–1780.
Ege GN. Lymphoscintigraphy, techniques and application in the management of breast carcinoma.Semin Nucl Med 1983; 13: 26–34.
Gill PG, Hall VE, Kirkwood I, Chatterton BE, Coventry B, Vernon-Roberts E. Lymphoscintigraphy for locating the sentinel lymph node in patients with breast cancer.Breast 1997; 6: 225. (abstract)
Kapteijn AE, Nieweg OE, Petersen JL, Rutgers EJ, Hart AA, Van Dongen JA, et al. Identification and biopsy of the sentinel node in breast cancer.Eur J Surg Oncol 1998; 24: 427–430.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe.Surg Oncol 1993; 2: 335–340.
Borgstein PJ, Pijpers R, Comans EF, Van Diest PS, Boom RP, Meijer S, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.J Am Coll Surg 1998; 186: 275–283.
Khalkhali I, Cutrone JA, Mena IG, Diggles LE, Venegas RJ, Vargas HI. Scintimammography: The complementary role of99mTc Sestamibi prone breast imaging for the diagnosis of breast carcinoma.Radiology 1995; 196: 421–426.
Burak Z, Argon M, Memis A, Erdem S, Balkan Z, Duman Y. Evaluation of palpable breast masses with99mTc MIBI: A comparative study with mammography and ultrasonography.Nucl Med Commun 1994; 15: 604–612.
Kao C, Wang S, Liu T. The use of99mTc methoxybutylisonitrile breast scintigraphy to evaluate palpable breast masses.Eur J Nucl Med 1994; 21: 432–436.
Maffioli L, Agresti R, Chiti A, Crippa F, Gasparini M, Greco M, et al. Prone, scintimammography in patients with non-palpable breast lesions.Anticancer Res 1996; 16: 1269–1274.
Palmedo I, Schonburg A, Grunwald F, Mallmann P, Krebs D, Biersach HJ.99mTc MIBI scintimammography for suspicious breast lesions.J Nucl Med 1996; 37: 626–674.
Khalkhali I, Iraniha S, Diggles LE, Cutrone JA, Mishkin FS: Scintimammography: the new role of Technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma.The Quart J Nucl Med 1997; 41: 231–238.
Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J.99mTechnetium Sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement.J Nucl Med 1995; 36: 52 (abstract)
Lam WWM, Yang WT, Chan YL, Stewart IET, Metrevelli C, King W. Detection of axillary lymph node metastases in breast carcinoma by99mTc MIBI breast scintigraphy ultrasound and conventional mammography.Eur J Nucl Med 1996; 23: 498–503.
Maffioli LS, Seregni E, Chiesa C, Nerini-Molteni S, Gerali A, Bombardieri E. Detection of lymph node metastases by lymphoscintigraphy with a tumour-seeking tracer in breast cancer patients.Eur J Nucl Med 2000; 27: 744–746.
Uren RF, Howman-Giles RB, Thompson JF. The value of pre-operative lymphoscintigraphy in breast cancer treatment.Eur J Cancer 1998; 34: 203–204.
De Cicco C, Cremonesi M, Luini A, Bertolomei M, Grana C, Drisco G, et al. Lymphoscintigraphy and Radioguided Biopsy of the Sentinel axillary node in breast cancer.J Nucl Med 1998; 39 (12): 2080–2084.
Mariani G, Villa G, Gipponi M, Bianchi P, Buffoni F, Agnese G, et al. Mapping sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue dye, and intraoperative gamma probe.Cancer Biother Radiopharm 2000; 15 (3): 245–250.
Giuliano AE. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection.J Surg Oncol 1996; 62: 75–77.
Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.Ann Surg 1998; 227: 645–653.
Nieweg OE, Jansen L, Yaldes Olmos RA, Rutgers EJ, Peterse JL, Hoefnagel KA, et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer.Eur J Nucl Med 1999; 26 (suppl): S11–16.
Van der Ent FWC, Kengen RAM, Van der Pol HAG, Hoofwijk AGM. Sentinel node biopsy in 70 unselected patients with breast cancer: increased feasibility by using 10 mCi radiocolloid in combination with ablue dye tracer.Eur J Surg Oncol 1999; 25: 24–29.
Kramer L. Lymphoscintigraphy: Radiopharmaceutical Selection and Methods.Nucl Med Biol 1990; 17 (1): 57–63.
Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patients with breast cancer.JAMA 1996; 276: 1818–1822.
Donahue EJ. Sentinel node imaging and biopsy in breast cancer patients.Am J Surg 2001; 182 (4): 426–428.
Kern KA. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye.J Am Coll Surg 1999; 189: 539–545.
Freneaux P, Nos C, Charvolin JY, Vincent-Salomon A, Zafrani B, Salmon RJ, et al. Value of macroscopic analysis for identification of axillary sentinel nodes detected by potent blue dye alone during breast cancer surgery.Ann Pathol 2000; 20: 545–548.
Ilum L, Bak M, Olsen KE, Kryh D, Berg V, Axelsson CK. Sentinel node localization in breast cancer patients using intradermal dye injection.Acta Oncol 2000; 39: 423–428.
About this article
Cite this article
Aras, G., Arican, P., Çam, R. et al. Identification of sentinel lymph node in breast cancer by lymphoscintigraphy and surgical gamma probe with peritumoral injection of scintimammographic agent “99mTc MIBI”. Ann Nucl Med 16, 121–126 (2002). https://doi.org/10.1007/BF02993715
- 99mTc MIBI
- surgical gamma probe
- breast cancer
- sentinel lymph node